Elevai Labs Inc. announced that its subsidiary, Elevai Skincare Inc., completed a clinical study on the effectiveness of its topical exosome product, Elevai enfinity, showing it to be safe and tolerable for improving facial appearance in participants aged 40-70 with mild to moderate photoaging.